FDA Panel Recommends Approval of Oral Fingolimod for Relapsing MS

Jun 10, 2010

FDA Panel Recommends Approval of Oral Fingolimod for Relapsing MS -- If agency follows advice, it would become first oral disease-modifying therapy for MS

A U.S. Food and Drug Administration advisory committee today recommended that the agency approve marketing of fingolimod capsules (formerly called Gilenia, Novartis International AG) for the treatment of relapsing multiple sclerosis. If approved, fingolimod would be the first oral disease-modifying therapy for the treatment of MS. While the FDA is not required to follow the recommendations of its advisory committees, it usually does. According to Novartis, the agency is expected to make a final decision about whether to approve the drug in September 2010.

READ MORE

*

Share |

*

****************************************************************

"Providing You with 'MS Views and News', is what we do"

Keep Informed and up-to-date with information concerning

 Multiple Sclerosis when registered at

the MS Views and News website.

(This will take 20-25 seconds and will empower you

 with informaton and learning)

Thank you for allowing me to help to keep you informed

****************************************************************